Q4 Earnings Forecast for OmniAb Issued By HC Wainwright

OmniAb, Inc. (NASDAQ:OABI) – Equities research analysts at HC Wainwright issued their Q4 2025 earnings per share estimates for OmniAb in a note issued to investors on Wednesday, March 19th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.15) per share for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for OmniAb’s FY2029 earnings at ($0.29) EPS.

OmniAb (NASDAQ:OABI) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.01. OmniAb had a negative return on equity of 20.97% and a negative net margin of 308.78%. The firm had revenue of $10.80 million during the quarter, compared to analysts’ expectations of $10.13 million. During the same period in the prior year, the firm posted ($0.14) earnings per share.

Separately, Benchmark cut their price objective on OmniAb from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday.

OmniAb Stock Up 11.5 %

OABI opened at $2.53 on Friday. OmniAb has a 12-month low of $2.23 and a 12-month high of $5.63. The stock has a market cap of $357.28 million, a price-to-earnings ratio of -4.08 and a beta of -0.14. The business has a 50 day moving average of $3.34 and a 200-day moving average of $3.77.

Insider Activity

In related news, CFO Kurt A. Gustafson sold 15,526 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total transaction of $50,304.24. Following the sale, the chief financial officer now owns 212,720 shares of the company’s stock, valued at $689,212.80. This trade represents a 6.80 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Charles S. Berkman sold 25,489 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total value of $82,584.36. Following the sale, the insider now directly owns 343,190 shares in the company, valued at approximately $1,111,935.60. This trade represents a 6.91 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 112,260 shares of company stock worth $376,601. Insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Squarepoint Ops LLC lifted its holdings in OmniAb by 33.3% during the 4th quarter. Squarepoint Ops LLC now owns 39,264 shares of the company’s stock worth $139,000 after buying an additional 9,809 shares during the period. Sherbrooke Park Advisers LLC lifted its holdings in OmniAb by 53.5% during the 4th quarter. Sherbrooke Park Advisers LLC now owns 17,226 shares of the company’s stock worth $61,000 after buying an additional 6,001 shares during the period. ProShare Advisors LLC lifted its stake in shares of OmniAb by 29.9% in the 4th quarter. ProShare Advisors LLC now owns 31,724 shares of the company’s stock valued at $112,000 after purchasing an additional 7,302 shares during the period. Northeast Financial Consultants Inc acquired a new position in shares of OmniAb in the 4th quarter valued at about $393,000. Finally, Millennium Management LLC lifted its stake in shares of OmniAb by 49.7% in the 4th quarter. Millennium Management LLC now owns 186,745 shares of the company’s stock valued at $661,000 after purchasing an additional 61,993 shares during the period. 72.08% of the stock is owned by institutional investors and hedge funds.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.